SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias shares drew attention after reports of CEO Jensen Huangs admitted affair with a woman alleged to have ties to Chinese intelligence prompted the board to open an independent investigation. Traders debated whether the controversy could threaten Huangs leadership or pose a national-security risk, while many dip buyers argued it does not change Nvidias AI-chip business fundamentals.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A weaker-than-expected Q3 revenue report and sequential sales decline are driving IBRXs sharp selloff, with traders questioning ANKTIVAs commercial uptake and raising concerns about competition, cash burn, and possible dilution. The reaction is divided: some see the results as evidence of weak execution, while others argue the BCG-naive trial success and Israeli approval support longer-term growth.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims is in focus around its quarterly results and its Eli Lilly deal to offer branded obesity drugs through its platform. Traders are split on whether the expanded GLP-1 offering can support growth, with concerns that lower margins could offset the benefit; some also speculate about an earnings leak, without evidence.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Discussion centers on the FDAs pending decision on Capricors deramiocel application for Duchenne muscular dystrophy, with traders focused on HOPE-3 upper-limb data and a letter from trial investigators urging approval. Many expect approval and speculate about a short squeeze, while others stress the binary risk of a rejection or CRL amid lingering FDA concerns.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A sharp rally into The Trade Desks quarterly earnings has traders debating whether optimism about a possible beat and heavy short interest could fuel further gains. Others see the move as a pre-earnings pump and expect a reversal, citing the companys recent weakness and concerns about advertising growth and guidance.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs preliminary third-quarter results, which showed strong sales and EBITDA growth, alongside Brad Jacobs bullish conference-call comments, have renewed optimism around the building-products roll-up strategy. Traders celebrated the rebound and speculated about short covering, though some remain cautious after the stocks steep decline.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Concern over a congressional report alleging Webull understated its China tiesand related securities lawsuitsdominates discussion of the stocks weakness. Bulls call the claims misleading and view the selloff as a buying opportunity ahead of earnings, while bears worry the allegations could sustain a China-risk discount.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly results beat expectations and management raised its revenue outlook on continued BRIUMVI growth, but shares fell as traders debated a sell-the-news reaction and alleged short-selling pressure. The upcoming Phase 3 readout for subcutaneous BRIUMVI is a major focus for investors looking beyond the earnings report.

Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. The company was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Wilmington, DE.

Clover Health Investments Corp - Ordinary Shares - Class A

Clover Health Investments Corp

Clover Health is drawing attention after traders reacted to strong Q3 results, improved full-year guidance, and continued profitability and membership growth. Bulls welcomed the results and renewed move above $5, while others questioned the muted reaction and the lack of concrete Counterpart Health software-revenue details.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Heavy selling is centered on concerns about Arrowheads commercial execution, with traders criticizing Redemplos sales and the companys losses while comparing its launch with Ioniss Tryngolza. Some see weak competitor sales as an opening for Redemplo, but others question whether uptake and revenue justify the companys valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NOVONIX (NASDAQ:NVX) Trading Down 1.8%  - Here's What Happened

NOVONIX (NASDAQ:NVX) Stock Price Down 1.8% - Here's What Happened...

NOVONIX Limited (OTCMKTS:NVNXF) Sees Large Drop in Short Interest

NOVONIX Limited (OTCMKTS:NVNXF - Get Free Report) saw a large decline in short interest in the month of March. As of March 31st, there was short interest totaling 41,692 shares, a decline of 33.3% from the March 15th total of 62,461 shares. Based on an average daily trading volume, of 153,935...

NOVONIX (NASDAQ:NVX) Stock Price Down 3.7% - Time to Sell?

NOVONIX (NASDAQ:NVX) Shares Down 3.7% - What's Next...

Wall Street Zen Downgrades NOVONIX (NASDAQ:NVX) to Sell

Wall Street Zen downgraded shares of NOVONIX from a "hold" rating to a "sell" rating in a research note on Saturday...

NOVONIX Limited Sponsored ADR (NASDAQ:NVX) Sees Significant Growth in Short Interest

NOVONIX Limited Sponsored ADR (NASDAQ:NVX - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling...

NOVONIX (NASDAQ:NVX) Shares Down 2.8% - Here's What Happened

NOVONIX (NASDAQ:NVX) Stock Price Down 2.8% - What's Next...

Nasdaq, S&P 500 Futures Edge Lower Ahead Of CPI Data: Why NVDA, AAPL, TSLA, RIVN, MRNA, AMAT, IREN Are On Traders' Radar Today

Equity

Data on Stocktwits showed retail traders remained bearish on SPY and ‘extremely bearish’ on QQQ.


NOVONIX Limited Sponsored ADR (NASDAQ:NVX) Short Interest Update

NOVONIX Limited Sponsored ADR (NASDAQ:NVX - Get Free Report) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling...

Short Interest in NOVONIX Limited (OTCMKTS:NVNXF) Declines By 34.0%

NOVONIX Limited (OTCMKTS:NVNXF - Get Free Report) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totaling 43,497 shares, a decline...

NOVONIX (OTCMKTS:NVNXF) Stock Price Up 7.6% - Here's What Happened

NOVONIX (OTCMKTS:NVNXF) Trading Up 7.6% - Time to Buy...

NOVONIX Ltd. engages in the revolutionizing the global lithium-ion battery industry with innovative, sustainable technologies, high-performance materials, and more efficient production methods. The firm manufactures industry battery cell testing equipment, is growing its high-performance synthetic graphite material manufacturing operations, and has developed a patented all-dry, zero-waste cathode synthesis process. The firm operates through the following segments: Battery Materials, Battery Technology, and Graphite Exploration. NOVONIX was founded by Gregory Alexander John Baynton in April 2012 and is headquartered in Brisbane, Australia.

Novonix Limited - ADR

Bullish Sentiment

<ul class="summary-bullets"><li>Investors awaited key inflation data that may determine the Fed’s next move.</li><li>Economists expect headline inflation to cool to 2.5% year-over-year.</li><li>Tariff developments and earnings reports added to the cautious tone.</li></ul>U.S. stock futures were lower early Friday as investors await the January Consumer Price Index (CPI) report before the bell today, with consensus expecting headline inflation to cool to 2.5% year-on-year (YoY). The inflation print could shape the Federal Reserve’s rate expectations over the next few weeks.&nbsp;As of 3:00 a.m. ET on Friday, Dow, S&amp;P 500, and Nasdaq futures and Russell 2000 futures were lower by 0.1%.&nbsp;&nbsp;Meanwhile, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has remained ‘bearish’, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, stayed ‘extremely bearish’ amid high message volumes.&nbsp;U.S. markets will be closed on Monday, Feb. 16, for Presidents' Day.Trending Stocks To WatchNvidia (NVDA):&nbsp;The company is reportedly set to lease a data center funded by $3.8 billion in junk bonds.&nbsp;Apple (AAPL):&nbsp;The stock posted its worst day since April in yesterday’s session. Reports suggested further delays to AI-powered Siri upgrades and scrutiny around Apple News.&nbsp;Palantir (PLTR):&nbsp;This stock is under scrutiny following a thesis from "Big Short" investor Michael Burry targeting a 60% collapse, even as DA Davidson maintains its "Buy" rating, citing no new cause for alarm.Applied Materials (AMAT):&nbsp;The semiconductor equipment giant bucked the tech trend with a blowout quarterly report and an upbeat guidanceTesla (TSLA):&nbsp;The U.S. Commerce Department finalized duties exceeding 160% on Chinese battery-grade graphite, potentially raising costs for domestic EV makers. On the other hand,&nbsp;Novonix (NVX)&nbsp;stands to be a big winner following this policy move.&nbsp;Rivian (RIVN):&nbsp;Saw a strong surge in after-hours trade on a revenue beat. But watch for any impact on the R2 rollout from the new graphite tariffs.&nbsp;Eli Lilly (LLY):&nbsp;Reuters reports the company has built a $1.5 billion stockpile of its experimental weight-loss pill,&nbsp;orforglipron, ahead of an April FDA decision.Moderna (MRNA): The biotech major is set to report earnings on Friday. Its shares fell roughly 10% this week after an FDA setback involving an investigational flu vaccine.Rocket Lab (RKLB):&nbsp;The company is prepping a Mach 20 hypersonic test mission for late February.IREN: The stock will be on retail radar after being added to the MSCI USA Index.Meanwhile, reports from the&nbsp;Financial Times suggest President Trump plans to scale back some steel and aluminum tariffs.&nbsp;Other tickers trending on Stocktwits at the time of writing included Freshworks Inc (FRSH), Pinterest (PINS), Churchill Capital (CCCX) and DraftKings Inc (DKNG), among others.&nbsp;Other Catalysts To WatchOn the economic front, investors will be monitoring the release of the consumer price index at 8:30 am ET.&nbsp; On the earnings radar, investors will also be watching for the quarterly reports from Moderna (MRNA), Wendy’s (WEN), Cameco (CCJ), and&nbsp;Trump Media &amp; Technology (DJT), among others, today.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Data on Stocktwits showed retail traders remained bearish on SPY and ‘extremely bearish’ on QQQ. Why NVDA, AAPL, TSLA, RIVN, MRNA, AMAT, IREN Are On Traders' Radar Today.

Apple Inc

Applied Materials Inc.

IREN Limited

Moderna Inc

Rivian Automotive Inc

Rocket Lab USA Inc

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Current Price	$2.13
Prev Close	$2.12
Open	$2.13
Dividend Yield	0.00%
50-Day Moving Average	$2.57
Beta	1.78
Avg. Volume	22,985.97
PE Ratio	-0.40

52-Week High	$16.15
52-Week Low	$1.99
Market Capitalization	$52.89M
EPS (Annual)	-$5.45
Price to Book	0.34
Revenue Per Employee	$29,286.51

Feed

News

Sentiment

Fundamentals

Info

NVX Fundamentals